Infections and Biologic Therapy in Rheumatoid Arthritis. Our Changing Understanding of Risk and Prevention.

Rheumatic Disease Clinics of North America

Volumn 38, Issue 4, 2012, Pages 727-745

  Winthrop, Kevin L ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Biologic therapy; Infection prevention; Infection risk; Infections; Rheumatoid arthritis; Screening

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIBIOTIC AGENT; BCG VACCINE; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INFLUENZA VACCINE; METHOTREXATE; PLACEBO; PNEUMOCOCCUS VACCINE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SIMPON; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; VARICELLA ZOSTER VACCINE;

ABDOMINAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEATH; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; IMMUNOGLOBULIN DEFICIENCY; INFECTION; INFECTION PREVENTION; INFECTION RISK; INFECTIOUS ARTHRITIS; INFECTIOUS PNEUMONIA; INFLUENZA; LOW DRUG DOSE; NONHUMAN; OPPORTUNISTIC INFECTION; OSTEOMYELITIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SKIN INFECTION; TUBERCULOSIS;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; HUMANS; OPPORTUNISTIC INFECTIONS; PREDNISOLONE; RISK FACTORS; VACCINATION;

EID: 84868384108     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2012.08.019     Document Type: Review

References (95)

1. Wagner U.G., Koetz K., Weyand C.M., et al. Perturbation of the T cell repertoire in rheumatoid arthritis. Proc Natl Acad Sci U S A 1998, 95(24):14447-14452.
2. Vallejo A.N., Weyand C.M., Goronzy J.J. T-cell senescence: a culprit of immune abnormalities in chronic inflammation and persistent infection. Trends Mol Med 2004, 10(3):119-124.
3. Doran M.F., Crowson C.S., Pond G.R., et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002, 46(9):2287-2293.
4. Dixon W.G., Kezouh A., Bernatsky S., et al. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis 2011, 70(6):956-960.
5. Wolfe F., Caplan L., Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006, 54(2):628-634.
6. Grijalva C.G., Kaltenbach L., Arbogast P.G., et al. Initiation of rheumatoid arthritis treatments and the risk of serious infections. Rheumatology (Oxford) 2010, 49(1):82-90.
7. Schneeweiss S., Setoguchi S., Weinblatt M.E., et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007, 56(6):1754-1764.
8. Curtis J.R., Patkar N., Xie A., et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007, 56(4):1125-1133.
9. Franklin J., Lunt M., Bunn D., et al. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis 2007, 66(3):308-312.
10. Strangfeld A., Eveslage M., Schneider M., et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?. Ann Rheum Dis 2011, 70(11):1914-1920.
11. Jick S.S., Lieberman E.S., Rahman M.U., et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006, 55(1):19-26.
12. Dirac M.A., Horan K.L., Doody D.R., et al. Environment or host?: a case-control study of risk factors for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2012, [Epub ahead of print].
13. Hojo M., Iikura M., Hirano S., et al. Increased risk of nontuberculous mycobacterial infection in asthmatic patients using long-term inhaled corticosteroid therapy. Respirology 2012, 17(1):185-190.
14. Winthrop K.L., Furst D.E. Rheumatoid arthritis and herpes zoster: risk and prevention in those treated with anti-tumour necrosis factor therapy. Ann Rheum Dis 2010, 69(10):1735-1737.
15. Smitten A.L., Choi H.K., Hochberg M.C., et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 2008, 35(3):387-393.
16. Strangfeld A., Listing J., Herzer P., et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009, 301(7):737-744.
17. Yale S.H., Limper A.H. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996, 71(1):5-13.
18. Hyrich K., Symmons D., Watson K., et al. BSRBR Control Centre Consortium, British Society for Rheumatology Biologics Register. Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register. Ann Rheum Dis 2006, 65(7):895-898.
19. Clay H., Volkman H.E., Ramakrishnan L. Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity 2008, 29(2):283-294.
20. Lin Y.C., Yeh C.J., Wang L.H., et al. The effect of CCND1 +870A>G and VEGF +936C>T polymorphisms on oral cancer development and disease-free survival in a Taiwan population. Oral Oncol 2012, 48(6):535-540.
21. Rothe J., Lesslauer W., Lotscher H., et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993, 364(6440):798-802.
22. Deepe G.S. Modulation of infection with Histoplasma capsulatum by inhibition of tumor necrosis factor-alpha activity. Clin Infect Dis 2005, 41(Suppl 3):S204-S207.
23. O'Brien D.P., Briles D.E., Szalai A.J., et al. Tumor necrosis factor alpha receptor I is important for survival from Streptococcus pneumoniae infections. Infect Immun 1999, 67(2):595-601.
24. Moore T.A., Lau H.Y., Cogen A.L., et al. Defective innate antibacterial host responses during murine Klebsiella pneumoniae bacteremia: tumor necrosis factor (TNF) receptor 1 deficiency versus therapy with anti-TNF-alpha. Clin Infect Dis 2005, 41(Suppl 3):S213-S217.
25. Bekker L.G., Freeman S., Murray P.J., et al. TNF-alpha controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J Immunol 2001, 166(11):6728-6734.
26. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295(19):2275-2285.
27. Leombruno J.P., Einarson T.R., Keystone E.C. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009, 68(7):1136-1145.
28. Singh J.A., Furst D.E., Bharat A., et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012, 64(5):625-639.
29. Burmester G.R., Mease P., Dijkmans B.A., et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009, 68(12):1863-1869.
30. Dommasch E.D., Abuabara K., Shin D.B., et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011, 64(6):1035-1050.
31. Pariser D.M., Leonardi C.L., Gordon K., et al. Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis. J Am Acad Dermatol 2012, 67(2):245-256.
32. Askling J., Fored C.M., Brandt L., et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007, 66(10):1339-1344.
33. Dixon W.G., Watson K., Lunt M., et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006, 54(8):2368-2376.
34. Dixon W.G., Symmons D.P., Lunt M., et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007, 56(9):2896-2904.
35. Grijalva C.G., Chen L., Delzell E., et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011, 306(21):2331-2339.
36. Galloway J.B., Hyrich K.L., Mercer L.K., et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011, 70(10):1810-1814.
37. Listing J., Strangfeld A., Kary S., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005, 52(11):3403-3412.
38. Wallis R.S., Broder M.S., Wong J.Y., et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004, 38(9):1261-1265.
39. Dixon W.G., Hyrich K.L., Watson K.D., et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010, 69(3):522-528.
40. Winthrop K., Baxter R., Liu L., et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 2012, [Epub ahead of print].
41. Saliu O.Y., Sofer C., Stein D.S., et al. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 2006, 194(4):486-492.
42. Bruns H., Meinken C., Schauenberg P., et al. Anti-TNF immunotherapy reduces CD8 + T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 2009, 119(5):1167-1177.
43. Plessner H.L., Lin P.L., Kohno T., et al. Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 2007, 195(11):1643-1650.
44. Askling J., Fored C.M., Brandt L., et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005, 52(7):1986-1992.
45. Wolfe F., Michaud K., Anderson J., et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004, 50(2):372-379.
46. Carmona L., Gomez-Reino J.J., Rodriguez-Valverde V., et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005, 52(6):1766-1772.
47. Winthrop K.L., Yamashita S., Beekmann S.E., et al. Infectious Diseases Society of America Emerging Infections Network. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the emerging infections network. Clin Infect Dis 2008, 46(11):1738-1740.
48. Winthrop K.L., Chang E., Yamashita S., et al. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg Infect Dis 2009, 15(10):1556-1561.
49. Salliot C., Dougados M., Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009, 68(1):25-32.
50. Gottenberg J.E., Ravaud P., Bardin T., et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010, 62(9):2625-2632.
51. Furst D.E., Keystone E.C., Braun J., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis 2011, 70(Suppl 1):i2-i36.
52. Curtis J.R., Xie F., Chen L., et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis 2011, 70(8):1401-1406.
53. Lutt J.R., Pisculli M.L., Weinblatt M.E., et al. Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis. J Rheumatol 2008, 35(8):1683-1685.
54. Tsutsumi Y., Ogasawara R., Kamihara Y., et al. Rituximab administration and reactivation of HBV. Hepat Res Treat 2010, 2010:182067.
55. Singh J.A., Wells G.A., Christensen R., et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011, (2). CD008794.
56. Bharat A., Xie F., Baddley J.W., et al. Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases. Arthritis Care Res (Hoboken) 2012, 64(4):612-615.
57. Molloy E.S., Calabrese L.H. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum 2012, 64(9):3043-3051.
58. Furst D.E. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010, 39(5):327-346.
59. Rozelle A.L., Genovese M.C. Efficacy results from pivotal clinical trials with abatacept. Clin Exp Rheumatol 2007, 25(5 Suppl 46):S30-S34.
60. Kremer J.M., Genant H.K., Moreland L.W., et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006, 144(12):865-876.
61. Weinblatt M., Schiff M., Goldman A., et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007, 66(2):228-234.
62. Simon T.A., Askling J., Lacaille D., et al. Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment. Arthritis Res Ther 2010, 12(2):R67.
63. Bigbee C.L., Gonchoroff D.G., Vratsanos G., et al. Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice. Arthritis Rheum 2007, 56(8):2557-2565.
64. Schiff M., Keiserman M., Codding C., et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008, 67(8):1096-1103.
65. Schiff M.H., Kremer J.M., Jahreis A., et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011, 13(5):R141.
66. Koike T., Harigai M., Inokuma S., et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis 2011, 70(12):2148-2151.
67. Fleischmann R.M., Tesser J., Schiff M.H., et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65(8):1006-1012.
68. Genovese M.C., Cohen S., Moreland L., et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004, 50(5):1412-1419.
69. Maeshima K., Yamaoka K., Kubo S., et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 production by human CD4 + T cells. Arthritis Rheum 2012, 64(6):1790-1798.
70. Zerbini C.A., Lomonte A.B. Tofacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 2012, 8(4):319-331.
71. Tanaka Y., Suzuki M., Nakamura H., et al. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011, 63(8):1150-1158. Tofacitinib Study Investigators.
72. Kremer J.M., Cohen S., Wilkinson B.E., et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 2012, 64(4):970-981.
73. Doran M.F., Crowson C.S., Pond G.R., et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002, 46(9):2294-2300.
74. Dubost J.J., Soubrier M., De Champs C., et al. No changes in the distribution of organisms responsible for septic arthritis over a 20 year period. Ann Rheum Dis 2002, 61(3):267-269.
75. Kollef M.H., Shorr A., Tabak Y.P., et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005, 128(6):3854-3862.
76. Targonski P.V., Poland G.A. Pneumococcal vaccination in adults: recommendations, trends, and prospects. Cleve Clin J Med 2007, 74(6):401-406. 408-10, 413-4.
77. Kapetanovic M.C., Saxne T., Sjoholm A., et al. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006, 45(1):106-111.
78. Available at: Accessed August 16, 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm285431.htm.
79. Available at: Accessed August 16, 2012. http://www.aafp.org/online/en/home/publications/news/news-now/health-of-the-public/20120626juneacipmtg.html.
80. Oren S., Mandelboim M., Braun-Moscovici Y., et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 2008, 67(7):937-941.
81. Fomin I., Caspi D., Levy V., et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006, 65(2):191-194.
82. Winthrop K.L., Calabrese L.H. Let the fog be lifted: screening for hepatitis B virus before biological therapy. Ann Rheum Dis 2011, 70(10):1701-1703.
83. Vassilopoulos D., Calabrese L.H. Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol 2012, 8(6):348-357.
84. Oxman M.N., Levin M.J. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis 2008, 197(Suppl 2):S228-S236. Shingles Prevention Study Group.
85. Zhang J., Xie F., Delzell E., et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012, 308(1):43-49.
86. Winthrop K.L., Siegel J.N., Jereb J., et al. Tuberculosis associated with therapy against tumor necrosis factor alpha. Arthritis Rheum 2005, 52(10):2968-2974.
87. Beglinger C., Dudler J., Mottet C., et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly 2007, 137(43-44):620-622.
88. Winthrop K.L., Weinblatt M., Daley C.L. You can't always get what you want, but if you try sometimes (with two tests-TST and IGRA for tuberculosis), you get what you need. Ann Rheum Dis 2012, [Epub ahead of print].
89. Griffith D.E., Aksamit T., Brown-Elliott B.A., et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175(4):367-416.
90. van Ingen J., Boeree M., Janssen M., et al. Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy. Nat Clin Pract Rheumatol 2007, 3(7):414-419.
91. Komano Y., Tanaka M., Nanki T., et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol 2011, 38(7):1258-1264.
92. Salmon-Ceron D., Tubach F., Lortholary O., et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011, 70(4):616-623.
93. Greenberg J.D., Reed G., Kremer J.M., et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010, 69(2):380-386.
94. Winthrop K.L., Baxter R., Liu L., et al. The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy. Pharmacoepidemiol Drug Saf 2011, 20(3):229-235.
95. McDonald J.R., Zeringue A.L., Caplan L., et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009, 48(10):1364-1371.